The involvement of innate immunity and in particular the Toll-like receptors (TLRs) in many diseases has produced a growing interest in the development of agonists and antagonists of these receptors as therapeutic tools. In stroke, activation of TLR-4 produces a cascade of events which ends in inflammation and cellular damage.

After several years of research, activity and efficacy studies have been completed in animal models, in vitro and in vivo. Results indicate that ApTOLL has promising pharmacodynamic, pharmacokinetic and toxicity characteristics. AptaTargets first objective is the completion of regulatory preclinical studies required before starting with clinical trials. Second objective is to complete Clinical Trials Phase I and Phase IIa, required for demonstrating an adequate safety profile and effectiveness. Third objective is to build a pipeline of drug candidates for different clinical indications.